article thumbnail

Done Deal: LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals 

The Dermatology Digest

LEO Pharma now owns TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. All employees of Timber Pharmaceuticals will transition to LEO Pharma’s offices in New Jersey, US, the Company reports. The TMB-001 project continues as planned and without changes within LEO Pharma.

article thumbnail

Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO

The Dermatology Digest

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. in September 2023.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024. And the Skin Disease of the Year Is….

article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

Phyllis Hsieh is the visionary behind Conrex Pharmaceutical Corp. and the creator of SESHA SKIN THERAPY, a professional skincare brand powered by Patented enhancement technology (P.E.T ) technology. The Permeation Enhancement Technology is FDA-approved in pharmaceuticals.

article thumbnail

Distinct Pattern in Protein Production May Predict Severe Side Effects From Melanoma Treatment

The Dermatology Digest

Moreover, the researchers found that this heightened gene signature, as evidenced by the production of spleen tyrosine kinases, or the SYK pathway, did not interfere with the effectiveness of therapies in preventing recurrence of melanoma. The impact was connected only to side effects.

article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD).

article thumbnail

Case 2: Female, 15 Years Old

Dermatology Times

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.